NASDAQ : CNSP
CNS Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 4.75 USD (Oct 30, 2026, 2:47 PM EDT) · Market cap 6.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 6.81M | 6.21M | 5.61M | 4.77M | 5.97M | 4.68M |
| Research & Development | 10.11M | 9.77M | 9.29M | 14.10M | 9.30M | 9.81M |
| Operating Expenses | 16.91M | 15.99M | 14.90M | 18.87M | 15.27M | 14.49M |
| Operating Income | -16.91M | -15.99M | -14.90M | -18.87M | -15.27M | -14.49M |
| Interest Expense | -15.23K | -15.23K | -16.12K | -13.80K | -7.03K | -9.29K |
| Interest & Investment Income | 232.78K | 153.78K | 60.26K | 27.69K | ||
| Other Non Operating Income (Expenses) | -2.56K | -2.56K | ||||
| EBT Excluding Unusual Items | -16.70M | -15.85M | -14.86M | -18.85M | -15.27M | -14.50M |
| Pretax Income | -16.70M | -15.85M | -14.86M | -18.85M | -15.27M | -14.50M |
| Net Income | -16.70M | -15.85M | -14.86M | -18.85M | -15.27M | -14.50M |
| Net Income to Common | -16.70M | -15.85M | -14.86M | -18.85M | -15.27M | -14.50M |
| Shares Outstanding (Basic) | 2.18M | 443.37K | 31.82K | |||
| Shares Outstanding (Diluted) | 2.18M | 443.37K | 31.82K | |||
| EPS (Basic) | -7.66 | -35.75 | -466.89 | |||
| EPS (Diluted) | -7.66 | -35.75 | -466.89 | |||
| Free Cash Flow | -13.44M | -13.83M | -17.12M | -14.14M | -10.56M | -13.54M |
| Free Cash Flow Per Share | -6.16 | -31.19 | -537.90 | |||
| EBITDA | -16.90M | -15.98M | -14.90M | -18.86M | -15.26M | -14.47M |
| D&A For EBITDA | 14.92K | 3.92K | 3.31K | 4.13K | 11.76K | 13.07K |
| EBIT | -16.91M | -15.99M | -14.90M | -18.87M | -15.27M | -14.49M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 19.98M | 7.20M | 6.46M | 548.72K | 10.06M | 5.00M |
| Cash & Short-Term Investments | 19.98M | 7.20M | 6.46M | 548.72K | 10.06M | 5.00M |
| Other Receivables | 882.54K | |||||
| Receivables | 882.54K | |||||
| Prepaid Expenses | 1.86M | 856.30K | 1.29M | 839.59K | 2.51M | 2.47M |
| Other Current Assets | 73.00K | 45.49K | 20.64K | 202.86K | ||
| Total Current Assets | 21.92M | 8.10M | 8.66M | 1.59M | 12.56M | 7.48M |
| Property, Plant & Equipment | 15.00K | 17.70K | 6.00K | 4.93K | 5.66K | 16.11K |
| Long-Term Deferred Charges | 334.14K | |||||
| Other Long-Term Assets | 502.96K | 36.43K | 104.75K | 482.81K | 929.69K | |
| Total Assets | 21.94M | 8.62M | 8.70M | 1.70M | 13.05M | 8.76M |
| Accounts Payable | 3.74M | 3.77M | 2.20M | 5.83M | 4.51M | 1.98M |
| Accrued Expenses | 224.95K | |||||
| Short-Term Debt | 328.57K | 326.07K | 300.81K | 409.97K | 387.79K | |
| Total Current Liabilities | 3.74M | 4.10M | 2.52M | 6.13M | 4.92M | 2.59M |
| Total Liabilities | 3.74M | 4.10M | 2.52M | 6.13M | 4.92M | 2.59M |
| Common Stock | 2.00K | 633.00 | 118.00 | 2.00 | 1.62K | 949.00 |
| Additional Paid-In Capital | 126.00M | 104.80M | 90.60M | 65.13M | 58.85M | 41.60M |
| Retained Earnings | -107.80M | -100.28M | -84.42M | -69.57M | -50.72M | -35.44M |
| Shareholders' Equity | 18.20M | 4.52M | 6.18M | -4.43M | 8.13M | 6.16M |
| Total Liabilities & Equity | 21.94M | 8.62M | 8.70M | 1.70M | 13.05M | 8.76M |
| Total Debt | 328.57K | 326.07K | 300.81K | 409.97K | 387.79K | |
| Net Cash (Debt) | 19.98M | 6.87M | 6.14M | 247.91K | 9.65M | 4.62M |
| Net Cash Per Share | 9.16 | 15.50 | 192.79 | |||
| Filing Date Shares Outstanding | 1.46M | 811.45K | 245.37K | |||
| Total Common Shares Outstanding | 1.46M | 632.52K | 117.80K | |||
| Working Capital | 18.18M | 4.00M | 6.13M | -4.54M | 7.64M | 4.88M |
| Book Value Per Share | 12.45 | 7.15 | 52.43 | |||
| Tangible Book Value | 18.20M | 4.52M | 6.18M | -4.43M | 8.13M | 6.16M |
| Tangible Book Value Per Share | 12.45 | 7.15 | 52.43 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -16.70M | -15.85M | -14.86M | -18.85M | -15.27M | -14.50M |
| Depreciation & Amortization | 14.92K | 3.92K | 3.31K | 4.13K | 11.76K | 13.07K |
| Other Amortization | 334.14K | |||||
| Loss (Gain) From Sale of Assets | 2.56K | 2.56K | -190.00 | 498.00 | 3.11K | |
| Stock-Based Compensation | 108.73K | 187.73K | 1.44M | 1.01M | 1.20M | 1.72M |
| Change in Accounts Payable | 2.44M | 1.54M | -3.63M | 1.32M | 2.30M | 1.04M |
| Change in Other Net Operating Assets | 716.80K | 302.80K | -59.97K | 2.38M | 860.45K | -1.82M |
| Operating Cash Flow | -13.41M | -13.81M | -17.11M | -14.14M | -10.56M | -13.54M |
| Capital Expenditures | -28.18K | -18.18K | -4.19K | -3.90K | -4.42K | -5.75K |
| Investing Cash Flow | -28.18K | -18.18K | -4.19K | -3.90K | -4.42K | -5.75K |
| Short-Term Debt Repaid | -297.55K | -300.81K | -438.73K | -427.70K | -477.49K | |
| Total Debt Repaid | -308.55K | -297.55K | -300.81K | -438.73K | -427.70K | -477.49K |
| Net Debt Issued (Repaid) | -308.55K | -297.55K | -300.81K | -438.73K | -427.70K | -477.49K |
| Issuance of Common Stock | 21.72M | 14.05M | 23.40M | 5.28M | 16.04M | 4.99M |
| Other Financing Activities | -111.59K | 816.41K | -66.75K | -202.86K | ||
| Financing Cash Flow | 21.30M | 14.57M | 23.03M | 4.64M | 15.61M | 4.51M |
| Net Cash Flow | 7.86M | 739.64K | 5.91M | -9.51M | 5.05M | -9.03M |
| Free Cash Flow | -13.44M | -13.83M | -17.12M | -14.14M | -10.56M | -13.54M |
| Free Cash Flow Per Share | -6.16 | -31.19 | -537.90 | |||
| Levered Free Cash Flow | -7.94M | -6.96M | -12.68M | -8.00M | -5.73M | -7.60M |
| Unlevered Free Cash Flow | -7.93M | -6.95M | -12.67M | -7.99M | -5.73M | -7.60M |
| Cash Interest Paid | 15.27K | 15.27K | 13.60K | 13.80K | 8.09K | 9.77K |
| Change in Working Capital | 3.16M | 1.85M | -3.69M | 3.70M | 3.16M | -780.02K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 7.23M | 3.26M | 6.92M | 6.63M | 3.17M | 19.60M |
| Enterprise Value | -12.75M | -6.58M | -20.55K | 5.76M | -3.82M | 11.32M |
| Last Close Price | 5.00 | 5.25 | 72.24 | 38,100.04 | 72,000.07 | 632,166.32 |
| PB Ratio | 0.40 | 0.72 | 1.12 | -1.50 | 0.39 | 3.18 |
| P/TBV Ratio | 0.40 | 0.72 | 1.12 | 0.39 | 3.18 | |
| Debt / Equity Ratio | 0.07 | 0.05 | -0.07 | 0.05 | 0.06 | |
| Net Debt / Equity Ratio | -1.10 | -1.52 | -0.99 | 0.06 | -1.19 | -0.75 |
| Net Debt / EBITDA Ratio | 1.18 | 0.43 | 0.41 | 0.01 | 0.63 | 0.32 |
| Net Debt / FCF Ratio | 1.49 | 0.50 | 0.36 | 0.02 | 0.91 | 0.34 |
| Quick Ratio | 5.35 | 1.76 | 2.91 | 0.09 | 2.04 | 1.93 |
| Current Ratio | 5.87 | 1.98 | 3.43 | 0.26 | 2.55 | 2.88 |
| Return on Equity (ROE) | -106.62% | -296.30% | -1,703.39% | -1,018.78% | -213.68% | -144.15% |
| Return on Assets (ROA) | -58.01% | -115.35% | -179.08% | -159.83% | -87.50% | -73.58% |
| Return on Capital Employed (ROCE) | -92.90% | -353.50% | -241.30% | 425.60% | -187.70% | -235.00% |
| Earnings Yield | -154.69% | -486.73% | -214.67% | -284.36% | -482.14% | -73.97% |
| FCF Yield | -183.94% | -424.66% | -247.31% | -213.35% | -333.40% | -69.11% |
| Buyback Yield / Dilution | -1,105.07% | -1,293.23% |